Patents by Inventor Brian Keogh

Brian Keogh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of renal disease
    Patent number: 9234046
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: January 12, 2016
    Assignee: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • Composition and method for treatment of reperfusion injury and tissue damage
    Patent number: 8734788
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: May 27, 2014
    Assignee: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • Vaccinia virus protein A46 peptide and use thereof
    Patent number: 8722052
    Abstract: A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 79, SEQ ID NO 82, SEQ ID NO 85, SEQ ID NO 88, SEQ ID NO 91, SEQ ID NO 94, SEQ ID NO 97, SEQ ID NO 100, SEQ ID NO 103, SEQ ID NO 106, SEQ ID NO 109, SEQ ID NO 112, or SEQ ID NO 115. The peptide may comprise a delivery sequence such as a cationic peptide.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: May 13, 2014
    Assignee: The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth, near Dublin
    Inventors: Andrew Graham Bowie, Barry Noel Harrington, Tatyana Sergeevna Lysakova, Brian Keogh
  • Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody
    Patent number: 8580255
    Abstract: The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: November 12, 2013
    Assignee: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF RENAL DISEASE
    Publication number: 20120258103
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 11, 2012
    Applicant: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • COMPOSITION AND METHOD FOR TREATMENT OF REPERFUSION INJURY AND TISSUE DAMAGE
    Publication number: 20120141466
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Application
    Filed: August 4, 2008
    Publication date: June 7, 2012
    Applicant: Opsona Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • COMPOSITION AND METHOD FOR TREATMENT OF REPERFUSION INJURY AND TISSUE DAMAGE
    Publication number: 20110293601
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Application
    Filed: August 4, 2008
    Publication date: December 1, 2011
    Applicant: Opsona Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • A VACCINIA VIRUS PROTEIN A46 PEPTIDE AND USE THEREOF
    Publication number: 20110293641
    Abstract: A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 79, SEQ ID NO 82, SEQ ID NO 85, SEQ ID NO 88, SEQ ID NO 91, SEQ ID NO 94, SEQ ID NO 97, SEQ ID NO 100, SEQ ID NO 103, SEQ ID NO 106, SEQ ID NO 109, SEQ ID NO 112, or SEQ ID NO 115. The peptide may comprise a delivery sequence such as a cationic peptide.
    Type: Application
    Filed: November 17, 2009
    Publication date: December 1, 2011
    Inventors: Andrew Graham Bowie, Barry Noel Harrington, Tatyana Sergeevna Lysakova, Brian Keogh
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF RENAL DISEASE
    Publication number: 20100278817
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.
    Type: Application
    Filed: July 4, 2008
    Publication date: November 4, 2010
    Applicant: OPSONA Therapeutics Ltd.
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • Filamentous haemagglutinin in the treatment and/or prophylaxis of immune-mediated disorders
    Publication number: 20070190078
    Abstract: Filamentous haemagglutinin (FHA) or a derivative or mutant or fragment or variant or peptide thereof is useful in the prophylaxis and/or treatment of an immune-mediated disorder and/or an autoimmune disease. The FHA may include self or foreign antigens or peptides thereof.
    Type: Application
    Filed: October 14, 2004
    Publication date: August 16, 2007
    Inventors: Kingston Mills, Peter Mcguirk, Brian Keogh
  • Halogenated hydrocarbon recycling machine
    Patent number: 5263326
    Abstract: A halogenated hydrocarbon recycling machine M1 comprising a cylinder-emptying apparatus including means for transferring a vapour mixture from a cylinder 10 to a fluid storage reservoir R1, a cylinder-filling apparatus including means for filling the cylinder 10.sup.1 from the reservoir R1 and a fluid separating apparatus including means for separating from the vapour mixture of an emptied cylinder, a reusable halogenated hydrocarbon fluid for use by the cylinder filling apparatus.
    Type: Grant
    Filed: October 31, 1991
    Date of Patent: November 23, 1993
    Assignee: Team Aer Lingus
    Inventors: Mathias Block, Padraig Furlong, Brian Keogh, Brendan Farrell, John Byrne